Status:
UNKNOWN
To Evaluate and Compare p53 Epidermal Expression in Healthy Volunteers 3 Months After Treatment With a 2,940-nm Fractional Ablative Erbium Laser and Topical DNA Repair Enzymes
Lead Sponsor:
Moy-Fincher-Chipps Facial Plastics and Dermatology
Conditions:
p53 Expression
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The p53 gene is located on the short arm of chromosome 17 and serves as a tumor suppressor gene. Alteration in p53 is an early event in skin cancer development. Further, p53 is the most commonly mutat...
Eligibility Criteria
Inclusion
- clinical signs of sun damage
- post-auricular regions have been visibly sun exposed
Exclusion
- history of actinic keratoses or skin cancer on tested site
- active tanning
- currently taking hormonal replacement therapy
- using topical or oral treatments for for photo aging in previous 6 months
- are currently pregnant or lactating
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04277949
Start Date
April 1 2020
End Date
August 1 2020
Last Update
February 20 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.